Fexofenadine and Pseudoephedrine allergy relief tablets recalled for failed dissolution
Dr. Reddy's Laboratories is recalling a 12 HR Allergy & Congestion Relief product distributed nationwide because the tablets failed to meet dissolution specifications, which may affect drug effectiveness.
What this means for you
Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.
Our severity reasoning: This is an FDA Class III recall with no reported illnesses or injuries. The hazard is theoretical—failed dissolution may affect drug efficacy but poses no direct safety threat. Per the rubric, Class III recalls are typically scored 1 or 2.
Plain-English summary
Dr. Reddy's Laboratories, Inc. is recalling 12 HR Allergy & Congestion Relief tablets containing Fexofenadine HCl 60 mg and Pseudoephedrine HCl 120 mg. The recall affects 2496 cartons distributed nationwide in the USA.
The recall was issued because the product failed dissolution specifications. Dissolution specifications ensure that a tablet properly breaks down in the digestive system so the active ingredients can be absorbed and provide the intended therapeutic effect.
The affected product has the National Drug Code (NDC) 70000-0518-1, Lot #AC2103329G with an expiration date of January 2023. The product was distributed by Cardinal Health, Dublin, Ohio and manufactured by Dr. Reddy's Laboratories, Inc. in India.
Consumers who have this product should consult their healthcare provider or pharmacist for advice. The FDA classifies this as a Class III recall.
The recalled product
- Product
- 12 HR Allergy & Congestion Relief Fexofenadine HCl, 60 mg I Pseudoephedrine HCl, 120 mg Antihistamine I Nasal Decongestant, 20 Extended-Release Tablets USP, Distributed By Cardinal Health, Dublin, Ohio 43107, Made in India, NDC 70000-0518-1.
- Manufacturer
- Dr. Reddy's Laboratories, Inc.
- Hazard
- failed-dissolution
- reduced-efficacy
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: AC2103329G
- Exp 1/2023
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27